ADR Classification & Recognition | Internal Medicine... | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. ADR Classification and Recognition: A Clinical Pharmacology Guide [ Medical Education ](https://mdster.com/blog?category=medical-education) ADR Classification and Recognition: A Clinical Pharmacology Guide =================================================================== Mastering Type A vs Type B reactions, drug allergy vs intolerance, and serious ADR reporting for clinical practice. [ MDster Editorial Team ](https://mdster.com/about) · Aug 01, 2026 · 4 min read · 19 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ Clinical Pharmacology ](https://mdster.com/blog?tag=clinical-pharmacology) [ Adverse Drug Reactions ](https://mdster.com/blog?tag=adverse-drug-reactions) [ Prescribing Safety ](https://mdster.com/blog?tag=prescribing-safety) ![ADR Classification and Recognition: A Clinical Pharmacology Guide](https://mdster.com/storage/blog/images/adr-classification-and-recognition-a-clinical-pharmacology-guide.jpg) Share this article Share this post On this page 1. [ Categorizing ADRs: Type A vs Type B Reactions ](#categorizing-adrs-type-a-vs-type-b-reactions) 2. [ Type A: Augmented Pharmacological Responses ](#type-a-augmented-pharmacological-responses) 3. [ Type B: Bizarre (Idiosyncratic) Responses ](#type-b-bizarre-idiosyncratic-responses) 4. [ Comparing Type A and Type B Reactions ](#comparing-type-a-and-type-b-reactions) 5. [ Differentiating Drug Allergy from Intolerance ](#differentiating-drug-allergy-from-intolerance) 6. [ Immune-Mediated Allergy vs. Non-Immune Intolerance ](#immune-mediated-allergy-vs-non-immune-intolerance) 7. [ Pseudoallergic Reactions: A Crucial Clinical Trap ](#pseudoallergic-reactions-a-crucial-clinical-trap) 8. [ Post-Marketing Surveillance and Serious ADR Reporting ](#post-marketing-surveillance-and-serious-adr-reporting) 9. [ Defining a Serious Adverse Event ](#defining-a-serious-adverse-event) 10. [ Reporting Mechanisms and Regulatory Impact ](#reporting-mechanisms-and-regulatory-impact) 11. [ Key Takeaways ](#key-takeaways) 12. [ Conclusion ](#conclusion) 13. [ Frequently Asked Questions ](#blog-faqs) 14. [ References ](#references-heading) On this page 1. [ Categorizing ADRs: Type A vs Type B Reactions ](#categorizing-adrs-type-a-vs-type-b-reactions) 2. [ Type A: Augmented Pharmacological Responses ](#type-a-augmented-pharmacological-responses) 3. [ Type B: Bizarre (Idiosyncratic) Responses ](#type-b-bizarre-idiosyncratic-responses) 4. [ Comparing Type A and Type B Reactions ](#comparing-type-a-and-type-b-reactions) 5. [ Differentiating Drug Allergy from Intolerance ](#differentiating-drug-allergy-from-intolerance) 6. [ Immune-Mediated Allergy vs. Non-Immune Intolerance ](#immune-mediated-allergy-vs-non-immune-intolerance) 7. [ Pseudoallergic Reactions: A Crucial Clinical Trap ](#pseudoallergic-reactions-a-crucial-clinical-trap) 8. [ Post-Marketing Surveillance and Serious ADR Reporting ](#post-marketing-surveillance-and-serious-adr-reporting) 9. [ Defining a Serious Adverse Event ](#defining-a-serious-adverse-event) 10. [ Reporting Mechanisms and Regulatory Impact ](#reporting-mechanisms-and-regulatory-impact) 11. [ Key Takeaways ](#key-takeaways) 12. [ Conclusion ](#conclusion) 13. [ Frequently Asked Questions ](#blog-faqs) 14. [ References ](#references-heading) Imagine a patient on day five of IV vancomycin developing sudden facial flushing and hypotension during infusion, while another patient on trimethoprim-sulfamethoxazole presents with skin sloughing and mucosal erosions. Misdiagnosing the first as a severe IgE-mediated anaphylaxis leads to prematurely abandoning a first-line antibiotic, while missing the second can be fatal. Accurately recognizing and classifying adverse drug reactions (ADRs) is one of the most critical clinical skills you will master on the wards and on board examinations. Categorizing ADRs: Type A vs Type B Reactions --------------------------------------------- The classic Rawlins-Thompson classification system divides ADRs into two primary categories based on predictable pharmacology versus idiosyncratic patient response. Understanding this distinction instantly guides your bedside management: whether to hold and re-titrate the medication or permanently add it to the patient’s allergy list. ### Type A: Augmented Pharmacological Responses Type A reactions represent exaggerated, predictable responses to a drug's known pharmacology. They are dose-dependent, account for over 80% of all ADRs, and carry relatively low mortality despite high morbidity. Common clinical examples include: - **Hypoglycemia** from sulfonylureas or insulin therapy. - **Bradycardia and AV block** from high-dose beta-blockers. - **Nephrotoxicity** from aminoglycosides or calcineurin inhibitors. - **Bleeding complications** secondary to therapeutic anticoagulation. Because Type A reactions are dose-dependent, management usually involves reducing the dose, extending the dosing interval, or adjusting co-prescribed interacting drugs rather than permanently discontinuing a vital therapy. ### Type B: Bizarre (Idiosyncratic) Responses Type B reactions are unpredictable, dose-independent, and unlinked to the drug's primary pharmacological mechanism. Though far less common (accounting for 10–15% of ADRs), they carry significantly higher mortality rates and usually mandate immediate, permanent drug cessation. Key features of Type B reactions include: - **Immunological hypersensitivity**: Anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and DRESS syndrome. - **Pharmacogenomic idiosyncrasies**: Hemolysis in G6PD-deficient patients exposed to rasburicase or primaquine, or HLA-B\*5701-mediated abacavir hypersensitivity. - **Organ-specific toxicity**: Idiosyncratic drug-induced liver injury (DILI) from amoxicillin-clavulanate or isoniazid. ### Comparing Type A and Type B Reactions Clinical FeatureType A (Augmented)Type B (Bizarre)**Predictability**High (based on pharmacology)Low (idiosyncratic/immune)**Dose Dependency**Yes (proportional to dose)No (can occur at sub-therapeutic doses)**Incidence / Mortality**High incidence, low mortalityLow incidence, high mortality**Management**Dose reduction or interval changeImmediate cessation; never rechallenge Differentiating Drug Allergy from Intolerance --------------------------------------------- Mislabeling drug intolerance as a true allergy is a pervasive problem in clinical medicine, leading to inappropriate broad-spectrum antibiotic selection and increased healthcare costs. You must carefully dissect patient-reported "allergies" during every admission history. ### Immune-Mediated Allergy vs. Non-Immune Intolerance True drug allergy requires an immunologic mechanism, classified under the Coombs and Gell scheme (Types I–IV hypersensitivity). Type I reactions are IgE-mediated (e.g., penicillins causing urticaria, bronchospasm, or anaphylaxis within hours), while Type IV reactions are T-cell mediated (e.g., delayed maculopapular eruptions, SJS/TEN). In contrast, drug intolerance represents a non-immunologic, predictable adverse effect operating at normal therapeutic doses: - **GI distress or nausea** from erythromycin (motilin receptor agonism). - **Dry cough** from ACE inhibitors due to bradykinin accumulation. - **Myalgias** from statin therapy. - **Diarrhea** from oral clavulanic acid. ### Pseudoallergic Reactions: A Crucial Clinical Trap Do not confuse pseudoallergic (anaphylactoid) reactions with true IgE-mediated allergies. Pseudoallergies involve direct, non-immune-mediated histamine release from mast cells or alterations in leukotriene pathways. Classic examples include Vancomycin Flushing Syndrome (formerly "Red Man Syndrome") and NSAID-induced bronchospasm. Slow down the infusion rate or pre-treat with antihistamines rather than listing a permanent penicillin-like allergy entry in the chart. > ### Clinical Pearl: Board Exam High-Yield Point > > When a board question presents a patient who developed facial flushing and itching during a rapid vancomycin infusion, the correct management step is **slowing the infusion rate to over 60 minutes**, not discontinuing the drug or ordering skin prick testing. Reserve true allergic labeling for immune-mediated hypersensitivities. Post-Marketing Surveillance and Serious ADR Reporting ----------------------------------------------------- Pivotal Phase III clinical trials typically enroll only 1,000 to 3,000 carefully selected patients. Consequently, rare Type B adverse reactions (occurring in <1 in 10,000 patients) are almost never detected prior to drug approval. Post-marketing (Phase IV) surveillance relies heavily on clinician vigilance to identify these rare signals. ### Defining a Serious Adverse Event Under FDA guidelines, an adverse event is classified as "serious" if it results in any of the following clinical outcomes: - **Death** or a life-threatening clinical event. - **Inpatient hospitalization** or prolongation of an existing hospital stay. - **Persistent or significant disability** or incapacity. - **Congenital anomaly** or birth defect. - **Substantial medical intervention** required to prevent permanent impairment. ### Reporting Mechanisms and Regulatory Impact In the United States, healthcare providers report suspected serious ADRs voluntarily through the **FDA MedWatch (Form 3500)** program. When post-marketing surveillance uncovers consistent safety signals, regulatory authorities institute safety alerts, mandate **Black Box Warnings** on package inserts, or remove the drug from the market entirely. Always report unexpected or severe reactions, even if you are uncertain of the definitive causal relationship. Pharmacovigilance algorithms rely on aggregate clinical reporting to detect safety patterns early. Key Takeaways ------------- - **Type A ADRs** are dose-dependent, predictable extensions of drug pharmacology managed by dose titration. - **Type B ADRs** are idiosyncratic, dose-independent, immune- or genetic-mediated reactions requiring permanent drug withdrawal. - **Drug allergy** involves immune system activation (IgE or cell-mediated), whereas **drug intolerance** reflects predictable, non-immune side effects. - **Pseudoallergy** (e.g., vancomycin flushing) stems from direct mast cell histamine release and is mitigated by slowing infusion speed. - **Serious ADR reporting** via FDA MedWatch is essential for Phase IV pharmacovigilance and detecting rare, life-threatening drug toxicities. Conclusion ---------- Mastering ADR classification allows you to protect your patients from preventable harm while avoiding unnecessary drug restrictions. Always question listed drug "allergies," recognize predictable pharmacological effects, and report severe idiosyncratic events to safeguard public health. Frequently Asked Questions ---------------------------- ### What is the primary difference between an adverse drug event (ADE) and an adverse drug reaction (ADR)? An adverse drug event (ADE) is an umbrella term for any injury resulting from medical intervention related to a drug, including medication errors, overdose, and administration mistakes. An adverse drug reaction (ADR) is a subset of ADEs specifically referring to noxious, unintended responses occurring at normal therapeutic doses. ### How should a suspected Type B reaction like DRESS syndrome or SJS be managed? Immediate and permanent discontinuation of the offending drug is mandatory. Re-challenging the patient with the drug is strictly contraindicated. Management involves supportive care, burn unit or ICU transfer if severe skin involvement occurs, and prompt specialist consultation. ### Who is required to submit reports to the FDA MedWatch program? Reporting by healthcare professionals (physicians, nurses, pharmacists) and patients is voluntary using FDA Form 3500. However, mandatory reporting (Form 3500A) applies to pharmaceutical manufacturers, IND sponsors, and medical device user facilities when they become aware of a serious adverse event. ### Why are rare Type B adverse reactions often missed during pre-marketing clinical trials? Phase I-III clinical trials typically enroll 1,000 to 3,000 patients and exclude complex, multimorbid individuals. They lack the statistical power to detect idiosyncratic or immunologic reactions that occur at rates of 1 in 10,000 or lower, making post-marketing (Phase IV) surveillance essential. References (3) ------------------ 1. 1. [ Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. Oxford University Press; 1977. ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168391/) 2. 2. [ U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. ](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) 3. 3. [ National Center for Biotechnology Information. StatPearls: Adverse Drug Reactions. ](https://www.ncbi.nlm.nih.gov/books/NBK532949/) Keep going Turn reading into Internal Medicine performance ------------------------------------------------- - System‑based, exam‑style questions + explanations - Smarter review to reinforce weak topics - Build confidence with measurable progress [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features\*. No commitment. Cancel anytime. \*AI SOE Examiner is limited to 10 cases monthly for Advanced & Bundle subscribers. Explore topics: [ # Board Review ](https://mdster.com/blog?tag=board-review) [ # Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ # Clinical Pharmacology ](https://mdster.com/blog?tag=clinical-pharmacology) [ # Adverse Drug Reactions ](https://mdster.com/blog?tag=adverse-drug-reactions) [ # Prescribing Safety ](https://mdster.com/blog?tag=prescribing-safety) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Trauma-Informed Communication in Pediatrics: Principles & Clinical Practice 6 min read Jul 31, 2026 ](https://mdster.com/blog/trauma-informed-communication-in-pediatrics-principles-clinical-practice) [### Post-Anesthetic Shivering: Differential Diagnosis, Forced-Air Warming, and Meperidine 5 min read Jul 30, 2026 ](https://mdster.com/blog/post-anesthetic-shivering-differential-diagnosis-forced-air-warming-and-meperidine) [### Clinical Reasoning With Person-Centredness in Family Medicine 7 min read Jul 22, 2026 ](https://mdster.com/blog/clinical-reasoning-with-person-centredness-in-family-medicine) Related Posts ------------- [ ![Trauma-Informed Communication in Pediatrics: Principles & Clinical Practice](https://mdster.com/storage/blog/images/trauma-informed-communication-in-pediatrics-principles-clinical-practice.jpg) Medical Education ### Trauma-Informed Communication in Pediatrics: Principles & Clinical Practice Learn how to implement trauma-informed communication principles in pediatric care, avoid retraumatization during exams, and navigate mandatory reporting limits. 6 min read 0 comments ](https://mdster.com/blog/trauma-informed-communication-in-pediatrics-principles-clinical-practice) [ ![Managing Endocervical Dysplasia and Type 3 Transformation Zones](https://mdster.com/storage/blog/images/managing-endocervical-dysplasia-and-type-3-transformation-zones.jpg) Case Discussion ### Managing Endocervical Dysplasia and Type 3 Transformation Zones Explore the management of discordant cervical histology with ECC-proven CIN 3 in a Type 3 transformation zone, focusing on colposcopic criteria, HPV pathophysiology, and ASCCP surveillance. 5 min read 0 comments ](https://mdster.com/blog/managing-endocervical-dysplasia-and-type-3-transformation-zones) [ ![Post-Anesthetic Shivering: Differential Diagnosis, Forced-Air Warming, and Meperidine](https://mdster.com/storage/blog/images/post-anesthetic-shivering-differential-diagnosis-forced-air-warming-and-meperidine.jpg) Medical Education ### Post-Anesthetic Shivering: Differential Diagnosis, Forced-Air Warming, and Meperidine Master the treatment of post-anesthetic shivering. Learn how to rule out hypoxia and pain, utilize forced-air warming, and apply the meperidine concept. 5 min read 0 comments ](https://mdster.com/blog/post-anesthetic-shivering-differential-diagnosis-forced-air-warming-and-meperidine) [ ![Clinical Reasoning With Person-Centredness in Family Medicine](https://mdster.com/storage/blog/images/clinical-reasoning-with-person-centredness-in-family-medicine.jpg) Medical Education ### Clinical Reasoning With Person-Centredness in Family Medicine A high-yield Family Medicine review of person-centred clinical reasoning: assess function, elicit ICE, build a biopsychosocial formulation, and align plans with patient goals. 7 min read 0 comments ](https://mdster.com/blog/clinical-reasoning-with-person-centredness-in-family-medicine) [ ![Inflammation Resolution: NSAIDs, Eicosanoids, and Steroids](https://mdster.com/storage/blog/images/inflammation-resolution-nsaids-eicosanoids-and-steroids.jpg) Medical Education ### Inflammation Resolution: NSAIDs, Eicosanoids, and Steroids Inflammation resolution is an active process, not passive fade-out. Learn the lipid mediator switch, NSAID toxicities, and steroid mechanisms that matter on wards and boards. 7 min read 0 comments ](https://mdster.com/blog/inflammation-resolution-nsaids-eicosanoids-and-steroids) [ ![Routine Pediatric Tracheostomy Care and Common Complications](https://mdster.com/storage/blog/images/routine-pediatric-tracheostomy-care-and-common-complications.jpg) Medical Education ### Routine Pediatric Tracheostomy Care and Common Complications A high-yield pediatric review of routine tracheostomy care, emergency suctioning, granulation tissue, and the decannulation algorithm that prevents airway disasters. 8 min read 0 comments ](https://mdster.com/blog/routine-pediatric-tracheostomy-care-and-common-complications) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept